Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IMPDH2 | P12268 | 18/20 | 0.81 |
| ▸ | IMPDH1 | P20839 | 8/20 | 0.79 |
| ▸ | AAK1 | Q2M2I8 | 2/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1475861 | 0.90 | IMPDH2 (0.85) | IMPDH2IMPDH1AAK1 | |
| SCHEMBL1473815 | 0.90 | IMPDH2 (1.00) | IMPDH2IMPDH1AAK1 | |
| SCHEMBL6488186 | 0.89 | IMPDH2 (0.81) | IMPDH2IMPDH1AAK1 | |
| SCHEMBL1473171 | 0.89 | IMPDH2 (0.73) | IMPDH2IMPDH1AAK1 | |
| SCHEMBL1474014 | 0.89 | IMPDH2 (1.00) | IMPDH2IMPDH1AAK1 | |
| SCHEMBL14518602 | 0.88 | IMPDH2 (0.83) | IMPDH2IMPDH1AAK1 | |
| SCHEMBL1475401 | 0.88 | IMPDH2 (0.75) | IMPDH2IMPDH1AAK1 | |
| SCHEMBL1473844 | 0.88 | IMPDH2 (0.75) | IMPDH2IMPDH1AAK1 | |
| SCHEMBL1474340 | 0.87 | IMPDH2 (0.80) | IMPDH2IMPDH1AAK1 | |
| SCHEMBL1475591 | 0.87 | IMPDH2 (0.87) | IMPDH2IMPDH1AAK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6867299-B2 | Inosine monophosphate dehydrogenase (IMPDH); use as immunosuppressants, anticancer agents and antiviral agents | HOFFMANN-LA ROCHE INC. (US) | 2005-03-15 | — | — | US | disclosed |
| US-20020052513-A1 | Oxamide IMPDH inhibitors | HOFFMANN-LA ROCHE INC. | 2002-05-02 | — | — | US | disclosed |
| EP-1127883-A2 | Oxamides as IMPDH inhibitors | F. HOFFMANN-LA ROCHE AG (CH) | 2001-08-29 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020052513-A1 | Oxamide IMPDH inhibitors | IMPDH1, IMPDH2, IMPA1 | IMPDH2 2/4885IMPDH1 1/4885AAK1 2882/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.